Tivic reports FY2025 net loss $8.8M-$9.1M; pivots to immunotherapy with Entolimod

Valion Bio, Inc.

Operating expenses $7.9M in 2025 vs $4.5M in 2024; net loss before disc. ops $7.9M-$8.1M.
Cash $12.6M at Dec 31, 2025 vs $2.0M at prior year-end; working capital $12.4M.
Acquired global rights to Entolimod for acute radiation syndrome; discontinued ClearUP/VNS.
CEO Michael K. Handley appointed March 2026, succeeding Jennifer Ernst.
Engaged with BARDA, DTRA, NIH, NIAID for potential Entolimod funding or procurement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.